ES2066033T3 - Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2066033T3
ES2066033T3 ES90108284T ES90108284T ES2066033T3 ES 2066033 T3 ES2066033 T3 ES 2066033T3 ES 90108284 T ES90108284 T ES 90108284T ES 90108284 T ES90108284 T ES 90108284T ES 2066033 T3 ES2066033 T3 ES 2066033T3
Authority
ES
Spain
Prior art keywords
peptide variants
preparation
pharmaceutical compositions
compositions containing
trypsin inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90108284T
Other languages
English (en)
Inventor
Hans Prof Dr Fritz
Wolfgang Dr Gebhard
Rathindra Dr Das
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2066033T3 publication Critical patent/ES2066033T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)

Abstract

EL INVENTO CONCIERNE A LOS VARIANTES DE PEPTIDOS BASADOS EN LOS DOMINIOS ACTIVOS INHIBIDORES DE LA BICUNINA HUMANA (ES DECIR, EL COMPONENTE ACTIVO DEL INHIBIDOR DE LA INTER-(ALFA)-TRIPSINA, O DEL INHIBIDOR SERICO DE LA TRIPSINA, ESTABLE A LOS ACIDOS, O DEL INHIBIDOR DE LA TRIPSINA URICA); AL PROCEDIMIENTO DE PRODUCCION DE ESTOS VARIANTES DE PEPTIDOS MEDIANTE TECNOLOGIA GENETICA EN MICROORGANISMOS (BACTERIAS, EUCARIONTES INFERIORES), ASI COMO A LOS MEDICAMENTOS QUE CONTIENEN DICHOS VARIANTES PEPTIDICOS. ESTAS SUSTANCIAS SE CARACTERIZAN POR SU CAPACIDAD DE INHIBICION DE LAS PROTEASAS SERICAS, POR EJEMPLO, DE LA ELASTASA PANCREATICA Y GRANULOCITARIA, DE LA CATEPSINA G O DE LA CALICREINA DEL PLASMA.
ES90108284T 1989-05-13 1990-05-01 Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2066033T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3915689 1989-05-13
DE4001244 1990-01-18

Publications (1)

Publication Number Publication Date
ES2066033T3 true ES2066033T3 (es) 1995-03-01

Family

ID=25880860

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90108284T Expired - Lifetime ES2066033T3 (es) 1989-05-13 1990-05-01 Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (17)

Country Link
US (1) US5407915A (es)
EP (1) EP0401508B1 (es)
JP (2) JP3126975B2 (es)
KR (1) KR0156246B1 (es)
AT (1) ATE114332T1 (es)
AU (1) AU623769B2 (es)
CA (1) CA2016627C (es)
DE (1) DE59007737D1 (es)
DK (1) DK0401508T3 (es)
ES (1) ES2066033T3 (es)
GR (1) GR3015124T3 (es)
HU (1) HU214985B (es)
IE (1) IE65710B1 (es)
IL (1) IL94349A (es)
NZ (1) NZ233635A (es)
PH (1) PH27530A (es)
PT (1) PT94016B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
CA2055425A1 (en) * 1990-11-13 1992-05-14 Hideaki Morishita Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
DE573603T1 (de) * 1991-03-01 1999-05-06 Dyax Corp Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g.
CA2082226A1 (en) * 1991-11-08 1993-05-09 Hideaki Morishita Polypeptide, dna fragment encoding the same, drug composition containing the same and process for producing the same
IL104327A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP3570558B2 (ja) * 1993-05-01 2004-09-29 持田製薬株式会社 Ｄｎａ断片およびそれを含むベクター、該ベクターによって形質転換された形質転換体、該ベクターを用いる蛋白質の産生方法
US5650394A (en) * 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE529444T1 (de) * 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
WO1996026273A1 (en) * 1995-02-23 1996-08-29 Adeza Biomedical Corporation Polypeptides derived from urinastatin having calcium channel blocking activity and their use to delay premature delivery
WO1997033996A2 (en) * 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
CN1229138C (zh) * 1998-12-22 2005-11-30 拜尔公开股份有限公司 加速粘液纤毛的清除速率的方法
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
US6660482B1 (en) * 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
US6731695B2 (en) * 2001-03-27 2004-05-04 Aware, Inc. Systems and methods for implementing receiver transparent Q-mode
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1531791T3 (da) 2002-06-07 2010-11-01 Dyax Corp Forebyggelse og begrænsning af iskæmi
PT2386310T (pt) 2002-08-28 2019-02-05 Dyax Corp Métodos para preservar órgãos e tecidos
JP2007524348A (ja) * 2003-01-07 2007-08-30 ダイアックス、コープ クニッツドメインライブラリー
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
LT3459564T (lt) 2010-01-06 2022-03-10 Takeda Pharmaceutical Company Limited Plazmos kalikreiną surišantys baltymai
IL310186A (en) 2011-01-06 2024-03-01 Takeda Pharmaceuticals Co KALLIKREIN PLASMA BINDING PROTEINS
AU2015218704B2 (en) * 2014-02-24 2019-05-02 Takeda Gmbh UTI fusion proteins
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
CO2018007151A2 (es) 2015-12-11 2018-09-20 Dyax Corp Inhibidores de calicreína plasmática y usos de los mismos para tratar ataque de angioedema hereditario
TW202142562A (zh) 2020-03-05 2021-11-16 美商迪亞醫藥美國公司 烏司他丁多肽

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2601033B1 (fr) * 1986-07-02 1990-01-19 Transgene Sa Variants de l'alpha-antitryspine humaine glycosylee et procede pour la preparation
EP0255011A3 (en) * 1986-07-29 1988-11-23 Miles Inc. Human inter-alpha-trypsin inhibitor gene

Also Published As

Publication number Publication date
CA2016627C (en) 2000-08-22
PH27530A (en) 1993-08-18
EP0401508A3 (de) 1991-03-27
CA2016627A1 (en) 1990-11-13
IL94349A0 (en) 1991-03-10
DE59007737D1 (de) 1995-01-05
KR900017607A (ko) 1990-12-19
DK0401508T3 (da) 1995-05-15
AU5497090A (en) 1990-11-15
PT94016A (pt) 1991-01-08
IE901713L (en) 1990-11-13
HU214985B (hu) 1998-08-28
PT94016B (pt) 1997-05-28
NZ233635A (en) 1991-12-23
IL94349A (en) 1998-01-04
EP0401508A2 (de) 1990-12-12
AU623769B2 (en) 1992-05-21
GR3015124T3 (en) 1995-05-31
JP3126975B2 (ja) 2001-01-22
HU903010D0 (en) 1990-09-28
EP0401508B1 (de) 1994-11-23
US5407915A (en) 1995-04-18
IE65710B1 (en) 1995-11-15
JPH03255099A (ja) 1991-11-13
JP2001112492A (ja) 2001-04-24
ATE114332T1 (de) 1994-12-15
KR0156246B1 (ko) 1998-11-16

Similar Documents

Publication Publication Date Title
ES2066033T3 (es) Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE226636T1 (de) Serpin-resistenter t-pa; mutanten; gene
ATE310087T1 (de) Plasma-kallikrein inhibitoren vom kunitz-typ
MX9603775A (es) Proteinas inhibidoras del dominio de kunitz, derivadas del inhibidor del precursor de la beta-proteina amiloide de alzheimer.
MY116539A (en) New amino acid derivatives
NO930517L (no) Benzimidazolylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
WO1996035788A3 (en) Kunitz type protease inhibitors
SE9602646D0 (sv) Pharmaceutically-useful compounds
PT871454E (pt) Inibidores fosforosos que contem protease de cisteina e de serina
ID28008A (id) Senyawa-senyawa baru
DK0419099T3 (da) Proteiner med antikoagulationsegenskaber
ATE92935T1 (de) Serinproteaseinhibitoren und isolierungsverfahren dazu.
NZ319474A (en) Guanidino protease inhibitors
Groutas et al. Inhibitors of human neutrophil cathepsin G: structural and biochemical studies
Takahara et al. Mouse plasma trypsin inhibitors: Inhibitory spectrum of contrapsin and alpha-1-antitrypsin
PT666755E (pt) Inibicao da infeccao pelo vih
Hayashi et al. Fibrin (ogen) binding region in urinary protein c inhibitor
Rarabas et al. Investigations of thrombin inhibitors in fibrinolytic systems
Ecke et al. Alternative targeting of a serpin-type inhibitor by glycosaminoglycans (GAGs): Heparin binding of protein C inhibitor (pci) prevents its interaction with tissue kallikrein (tk)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 401508

Country of ref document: ES